BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults

被引:15
作者
Seidel, Alina [1 ]
Zanoni, Michelle [1 ]
Gross, Ruediger [1 ]
Krnavek, Daniela [1 ]
Erdemci-Evin, Suemeyye [1 ]
von Maltitz, Pascal [1 ]
Albers, Dan P. J. [1 ]
Conzelmann, Carina [1 ]
Liu, Sichen [1 ]
Weil, Tatjana [1 ]
Mayer, Benjamin [2 ]
Hoffmann, Markus [3 ,4 ]
Poehlmann, Stefan [3 ,4 ]
Beil, Alexandra [5 ]
Kroschel, Joris [5 ]
Kirchhoff, Frank [1 ]
Muench, Jan [1 ,6 ]
Mueller, Janis A. [1 ,7 ]
机构
[1] Ulm Univ, Inst Mol Virol, Med Ctr, Ulm, Germany
[2] Ulm Univ, Inst Epidemiol & Med Biometry, Ulm, Germany
[3] Leibniz Inst Primate Res, German Primate Ctr, Infect Biol Unit, Gottingen, Germany
[4] Georg August Univ Gottingen, Fac Biol & Psychol, Gottingen, Germany
[5] Univ Hosp Ulm, Cent Dept Clin Chem, Ulm, Germany
[6] Ulm Univ, Core Facil Funct Peptid, Med Ctr, Ulm, Germany
[7] Philipps Univ Marburg, Inst Virol, Marburg, Germany
关键词
COVID-19; delta; B; 1; 529; BA; humoral immunity; memory T cells; ChadOx1; nCoV-19; vaccination interval; COVID-19; VACCINE; IMMUNOGENICITY; SAFETY;
D O I
10.3389/fimmu.2022.882918
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In light of the decreasing immune protection against symptomatic SARS-CoV-2 infection after initial vaccinations and the now dominant immune-evasive Omicron variants, 'booster' vaccinations are regularly performed to restore immune responses. Many individuals have received a primary heterologous prime-boost vaccination with long intervals between vaccinations, but the resulting long-term immunity and the effects of a subsequent 'booster', particularly against Omicron BA.1, have not been defined. We followed a cohort of 23 young adults, who received a primary heterologous ChAdOx1 nCoV-19 BNT162b2 prime-boost vaccination, over a 7-month period and analysed how they responded to a BNT162b2 'booster'. We show that already after the primary heterologous vaccination, neutralization titers against Omicron BA.1 are recognizable but that humoral and cellular immunity wanes over the course of half a year. Residual responsive memory T cells recognized spike epitopes of the early SARS-CoV-2 B.1 strain as well as the Delta and BA.1 variants of concern (VOCs). However, the remaining antibody titers hardly neutralized these VOCs. The 'booster' vaccination was well tolerated and elicited both high antibody titers and increased memory T cell responses against SARS-CoV-2 including BA.1. Strikingly, in this young heterologously vaccinated cohort the neutralizing activity after the 'booster' was almost as potent against BA.1 as against the early B.1 strain. Our results suggest that a 'booster' after heterologous vaccination results in effective immune maturation and potent protection against the Omicron BA.1 variant in young adults.
引用
收藏
页数:11
相关论文
共 81 条
[1]   Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar [J].
Abu-Raddad, L. J. ;
Chemaitelly, H. ;
Ayoub, H. H. ;
AlMukdad, S. ;
Yassine, H. M. ;
Al-Khatib, H. A. ;
Smatti, M. K. ;
Tang, P. ;
Hasan, M. R. ;
Coyle, P. ;
Al-Kanaani, Z. ;
Al-Kuwari, E. ;
Jeremijenko, A. ;
Kaleeckal, A. H. ;
Latif, A. N. ;
Shaik, R. M. ;
Abdul-Rahim, H. F. ;
Nasrallah, G. K. ;
Al-Kuwari, M. G. ;
Butt, A. A. ;
Al-Romaihi, H. E. ;
Al-Thani, M. H. ;
Al-Khal, A. ;
Bertollini, R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (19) :1804-1816
[2]   SARS-CoV-2 T Cell Responses Elicited by COVID-19 Vaccines or Infection Are Expected to Remain Robust against Omicron [J].
Ahmed, Syed Faraz ;
Quadeer, Ahmed Abdul ;
McKay, Matthew R. .
VIRUSES-BASEL, 2022, 14 (01)
[3]  
[Anonymous], 2010, COMMON TERMINOLOGY C
[4]  
[Anonymous], 2010, Guideline on missing data in confirmatory clinical trials
[5]   BNT162b2 Vaccine Booster and Mortality Due to Covid-19 [J].
Arbel, Ronen ;
Hammerman, Ariel ;
Sergienko, Ruslan ;
Friger, Michael ;
Peretz, Alon ;
Netzer, Doron ;
Yaron, Shlomit .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (26) :2413-2420
[6]   Homologous and Heterologous Covid-19 Booster Vaccinations [J].
Atmar, R. L. ;
Lyke, K. E. ;
Deming, M. E. ;
Jackson, L. A. ;
Branche, A. R. ;
El Sahly, H. M. ;
Rostad, C. A. ;
Martin, J. M. ;
Johnston, C. ;
Rupp, R. E. ;
Mulligan, M. J. ;
Brady, R. C. ;
Frenck, R. W., Jr. ;
Backer, M. ;
Kottkamp, A. C. ;
Babu, T. M. ;
Rajakumar, K. ;
Edupuganti, S. ;
Dobrzynski, D. ;
Coler, R. N. ;
Posavad, C. M. ;
Archer, J., I ;
Crandon, S. ;
Nayak, S. U. ;
Szydlo, D. ;
Zemanek, J. A. ;
Islas, C. P. Dominguez ;
Brown, E. R. ;
Suthar, M. S. ;
McElrath, M. J. ;
McDermott, A. B. ;
Montefiori, D. C. ;
Eaton, A. ;
Neuzil, K. M. ;
Stephens, D. S. ;
Roberts, P. C. ;
Beigel, J. H. .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (11) :1046-1057
[7]   Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study [J].
Barda, Noam ;
Dagan, Noa ;
Cohen, Cyrille ;
Hernan, Miguel A. ;
Lipsitch, Marc ;
Kohane, Isaac S. ;
Reis, Ben Y. ;
Balicer, Ran D. .
LANCET, 2021, 398 (10316) :2093-2100
[8]   Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants [J].
Belik, Milja ;
Jalkanen, Pinja ;
Lundberg, Rickard ;
Reinholm, Arttu ;
Laine, Larissa ;
Vaisanen, Elina ;
Skon, Marika ;
Tahtinen, Paula A. ;
Ivaska, Lauri ;
Pakkanen, Sari H. ;
Hakkinen, Hanni K. ;
Ortamo, Eeva ;
Pasternack, Arja ;
Ritvos, Mikael A. ;
Naves, Rauno A. ;
Miettinen, Simo ;
Sironen, Tarja ;
Vapalahti, Olli ;
Ritvos, Olli ;
Osterlund, Pamela ;
Kantele, Anu ;
Lempainen, Johanna ;
Kakkola, Laura ;
Kolehmainen, Pekka ;
Julkunen, Ilkka .
NATURE COMMUNICATIONS, 2022, 13 (01)
[9]   Safety and Immunogenicity of Influenza A H5 Subunit Vaccines: Effect of Vaccine Schedule and Antigenic Variant [J].
Belshe, Robert B. ;
Frey, Sharon E. ;
Graham, Irene ;
Mulligan, Mark J. ;
Edupuganti, Srilatha ;
Jackson, Lisa A. ;
Wald, Anna ;
Poland, Gregory ;
Jacobson, Robert ;
Keyserling, Harry L. ;
Spearman, Paul ;
Hill, Heather ;
Wolff, Mark .
JOURNAL OF INFECTIOUS DISEASES, 2011, 203 (05) :666-673
[10]   Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial [J].
Borobia, Alberto M. ;
Carcas, Antonio J. ;
Perez-Olmeda, Mayte ;
Castano, Luis ;
Jesus Bertran, Maria ;
Garcia-Perez, Javier ;
Campins, Magdalena ;
Portoles, Antonio ;
Gonzalez-Perez, Maria ;
Garcia Morales, Maria Teresa ;
Arana-Arri, Eunate ;
Aldea, Marta ;
Diez-Fuertes, Francisco ;
Fuentes, Inmaculada ;
Ascaso, Ana ;
Lora, David ;
Imaz-Ayo, Natale ;
Baron-Mira, Lourdes E. ;
Agusti, Antonia ;
Perez-Ingidua, Carla ;
Gomez de la Camara, Agustin ;
Ramon Arribas, Jose ;
Ochando, Jordi ;
Alcami, Jose ;
Belda-Iniesta, Cristobal ;
Frias, Jesus .
LANCET, 2021, 398 (10295) :121-130